Person-First Language May Mitigate Stigmatization in Lung Cancer Screening

Commentary
Video

Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.

It is crucial to use person-first language to reduce potential feelings of stigmatization around lung cancer diagnoses and ensure that patients are receiving equitable treatment across the board, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.

In a conversation with CancerNetwork®, Carter-Bawa, director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery and Innovation, spoke about the prominent factors that may contribute to the stigmatization of lung cancer and thereby impact an individual’s decision to screen for potential disease. For example, she described how the act of smoking may instill feelings of blame and shame surrounding a lung cancer diagnosis and stated that avoiding the use of terms such as “smoker” in clinical communication may mitigate this stigmatization.

Transcript:

The most prominent factor boils down to blame and shame around smoking. Whether it is an underlying tone or message toward an individual or, very frankly, a blatant use of language to blame someone in the context of lung cancer. To give you an example, a person’s diagnosed with lung cancer and shares a diagnosis with a friend. The immediate response from the friend is saying something like, "I didn’t know you smoked." Somehow that act of smoking equates to deserving a deadly disease like lung cancer.

The point is that hearing that someone has lung cancer somehow automatically spurs the response that equates to blaming them for having the disease. This kind of public discourse around lung cancer has seeped into not just individuals diagnosed with lung cancer but backing it up to lung cancer screening with the same shame and blame feelings. Those are the prominent factors that contribute to feeling stigmatized.

I would love for my colleagues to take away envisioning a world where stigma in lung cancer doesn’t exist—that it’s just a historical blip that we look back on—and that we are treating people equitably across the board. [Where] we’re using person-first language and not referring to people as smoker and non-smoker in our scientific communication, our medical communication, or layman communications. That’s the biggest thing I would like colleagues to take away from this.

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Related Content